DE60042161D1 - Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen - Google Patents

Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen

Info

Publication number
DE60042161D1
DE60042161D1 DE60042161T DE60042161T DE60042161D1 DE 60042161 D1 DE60042161 D1 DE 60042161D1 DE 60042161 T DE60042161 T DE 60042161T DE 60042161 T DE60042161 T DE 60042161T DE 60042161 D1 DE60042161 D1 DE 60042161D1
Authority
DE
Germany
Prior art keywords
treatment
cardiovascular diseases
ppar delta
delta inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042161T
Other languages
English (en)
Inventor
Colin Neil Palmer
Helen Vosper
Charles Roland Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Dundee filed Critical University of Dundee
Application granted granted Critical
Publication of DE60042161D1 publication Critical patent/DE60042161D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
DE60042161T 1999-07-23 2000-07-19 Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen Expired - Lifetime DE60042161D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9917405.4A GB9917405D0 (en) 1999-07-23 1999-07-23 Methods of treatment and drug screening methods
PCT/EP2000/006986 WO2001007066A2 (en) 1999-07-23 2000-07-19 Ppar delta inhibitors for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
DE60042161D1 true DE60042161D1 (de) 2009-06-18

Family

ID=10857874

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042161T Expired - Lifetime DE60042161D1 (de) 1999-07-23 2000-07-19 Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen

Country Status (29)

Country Link
EP (1) EP1200114B1 (de)
JP (1) JP2003505058A (de)
KR (1) KR20020012323A (de)
CN (1) CN1364087A (de)
AR (1) AR027832A1 (de)
AT (1) ATE430577T1 (de)
AU (1) AU6825900A (de)
BR (1) BR0012661A (de)
CA (1) CA2378462A1 (de)
CO (1) CO5280202A1 (de)
CY (1) CY1109255T1 (de)
CZ (1) CZ2002247A3 (de)
DE (1) DE60042161D1 (de)
DK (1) DK1200114T3 (de)
ES (1) ES2326785T3 (de)
GB (1) GB9917405D0 (de)
HK (1) HK1046094B (de)
HU (1) HUP0201966A3 (de)
IL (1) IL147363A0 (de)
MX (1) MXPA02000880A (de)
MY (1) MY140626A (de)
NO (1) NO20020326L (de)
NZ (1) NZ573856A (de)
PL (1) PL205747B1 (de)
PT (1) PT1200114E (de)
SI (1) SI1200114T1 (de)
TR (2) TR200501763T1 (de)
WO (1) WO2001007066A2 (de)
ZA (1) ZA200200542B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677298B2 (en) 2000-07-20 2004-01-13 Bristol-Myers Squibb Company Regulators of PPARδ (β) and their use in the treatment of obesity and insulin resistance
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
GB0103809D0 (en) 2001-02-16 2001-04-04 Univ Dundee Methods
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
GB0302446D0 (en) * 2003-02-03 2003-03-05 Imp College Innovations Ltd Screening for modulators of fat storage
JPWO2004093910A1 (ja) * 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
EP1804813A4 (de) * 2004-09-27 2011-09-07 Vical Inc Formulierungen und verfahren zur behandlung von entzündlichen erkrankungen
DE102006033394A1 (de) * 2006-07-13 2008-01-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zum Auffinden von antiatherosklerotischen Substanzen
US8236831B2 (en) * 2007-01-08 2012-08-07 Seoul National University Industry Foundation Thiazole compound (as PPARδ) ligand and pharmaceutical, cosmetic and health food comprised thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1998008836A1 (fr) * 1996-08-27 1998-03-05 Shionogi & Co., Ltd. Derives de chromene-3-carboxylate
EP1410799B1 (de) * 1996-12-11 2010-03-31 Dana-Farber Cancer Institute, Inc. Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums
AU6773598A (en) * 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
WO1999000491A1 (fr) * 1997-06-27 1999-01-07 Ono Pharmaceutical Co., Ltd. Nouvel adn plasmidique contenant de l'adn de gene reporter et utilisation associee
JP4427825B2 (ja) * 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Also Published As

Publication number Publication date
CO5280202A1 (es) 2003-05-30
NO20020326D0 (no) 2002-01-22
NO20020326L (no) 2002-03-20
EP1200114B1 (de) 2009-05-06
EP1200114A2 (de) 2002-05-02
AR027832A1 (es) 2003-04-16
HK1046094A1 (en) 2002-12-27
ZA200200542B (en) 2003-07-30
WO2001007066A3 (en) 2001-08-09
BR0012661A (pt) 2002-04-09
CN1364087A (zh) 2002-08-14
KR20020012323A (ko) 2002-02-15
WO2001007066A2 (en) 2001-02-01
TR200501763T2 (tr) 2005-08-22
MY140626A (en) 2010-01-15
PL364749A1 (en) 2004-12-13
TR200200211T2 (tr) 2002-06-21
DK1200114T3 (da) 2009-08-03
MXPA02000880A (es) 2003-07-14
CZ2002247A3 (cs) 2002-11-13
IL147363A0 (en) 2002-08-14
SI1200114T1 (sl) 2009-10-31
CY1109255T1 (el) 2014-07-02
JP2003505058A (ja) 2003-02-12
ATE430577T1 (de) 2009-05-15
NZ573856A (en) 2010-06-25
ES2326785T3 (es) 2009-10-20
HK1046094B (zh) 2009-10-02
PT1200114E (pt) 2009-07-09
GB9917405D0 (en) 1999-09-22
TR200501763T1 (tr) 2009-03-23
HUP0201966A2 (en) 2002-09-28
AU6825900A (en) 2001-02-13
PL205747B1 (pl) 2010-05-31
CA2378462A1 (en) 2001-02-01
HUP0201966A3 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE376994T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE502004008604D1 (de) Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
ATE269866T1 (de) Intranasale zubereitungen zur behandlung sexueller störungen
NO20026008D0 (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE313540T1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE355067T1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60328494D1 (de) Verbessertes system zur behandlung der stressbedingten harninkontinenz
DE60042161D1 (de) Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition